Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYTR NASDAQ:LIFE NASDAQ:OTLK NASDAQ:TROV NASDAQ:TTNP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTRLadRx$0.09$0.05▼$0.86$4.14MN/A99,706 shs4,000 shsLIFEaTyr Pharma$1.76$1.08▼$2.45$131.12M1.19514,103 shs269,400 shsOTLKOncobiologics$1.03-5.1%$1.85$0.79▼$6.98$45.53M0.481.59 million shs1.25 million shsTROVCardiff Oncology$2.00-2.0%$16.75$0.70▼$3.46$22.02M1.04648,892 shs733,755 shsTTNPTitan Pharmaceuticals$4.30-0.5%$4.42$3.03▼$6.43$5.72M1.4144,000 shs11,389 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTRLadRx0.00%0.00%0.00%0.00%0.00%LIFEaTyr Pharma0.00%0.00%0.00%0.00%0.00%OTLKOncobiologics+2.86%+16.58%-53.85%-35.71%-81.79%TROVCardiff Oncology-0.49%-8.52%-16.39%-44.86%-24.72%TTNPTitan Pharmaceuticals-1.44%+6.08%-12.30%+0.95%-24.16%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTRLadRx$0.09$0.05▼$0.86$4.14MN/A99,706 shs4,000 shsLIFEaTyr Pharma$1.76$1.08▼$2.45$131.12M1.19514,103 shs269,400 shsOTLKOncobiologics$1.03-5.1%$1.85$0.79▼$6.98$45.53M0.481.59 million shs1.25 million shsTROVCardiff Oncology$2.00-2.0%$16.75$0.70▼$3.46$22.02M1.04648,892 shs733,755 shsTTNPTitan Pharmaceuticals$4.30-0.5%$4.42$3.03▼$6.43$5.72M1.4144,000 shs11,389 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTRLadRx0.00%0.00%0.00%0.00%0.00%LIFEaTyr Pharma0.00%0.00%0.00%0.00%0.00%OTLKOncobiologics+2.86%+16.58%-53.85%-35.71%-81.79%TROVCardiff Oncology-0.49%-8.52%-16.39%-44.86%-24.72%TTNPTitan Pharmaceuticals-1.44%+6.08%-12.30%+0.95%-24.16%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYTRLadRx 0.00N/AN/AN/ALIFEaTyr Pharma 0.00N/AN/AN/AOTLKOncobiologics 2.33Hold$9.60836.59% UpsideTROVCardiff Oncology 0.00N/AN/AN/ATTNPTitan Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TTNP, OTLK, CYTR, LIFE, and TROV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/29/2025OTLKOncobiologicsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral8/28/2025OTLKOncobiologicsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$3.008/28/2025OTLKOncobiologicsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral8/27/2025OTLKOncobiologicsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/15/2025OTLKOncobiologicsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$3.00(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYTRLadRxN/AN/AN/AN/AN/AN/ALIFEaTyr Pharma$350K0.00N/AN/A$1.54 per share0.00OTLKOncobiologicsN/AN/AN/AN/A($3.09) per shareN/ATROVCardiff Oncology$250K88.09N/AN/A$0.94 per share2.13TTNPTitan Pharmaceuticals$180K31.77N/AN/A$2.67 per share1.61Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYTRLadRxN/AN/A0.00N/AN/AN/AN/AN/AN/ALIFEaTyr Pharma-$50.39M-$0.90N/AN/AN/AN/A-56.92%-43.87%N/AOTLKOncobiologics-$75.37M-$0.57N/AN/AN/AN/AN/A-332.30%N/ATROVCardiff Oncology-$16.41M-$2.80N/A∞N/A-3,688.31%-202.00%-122.92%N/ATTNPTitan Pharmaceuticals-$4.71M-$2.95N/A∞N/AN/A-108.60%-95.64%N/ALatest TTNP, OTLK, CYTR, LIFE, and TROV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q3 2025OTLKOncobiologics-$0.42-$0.44-$0.02-$0.55$1.66 million$1.51 million8/14/2025Q2 2025TTNPTitan PharmaceuticalsN/A-$0.65N/A-$0.65N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYTRLadRxN/AN/AN/AN/AN/ALIFEaTyr PharmaN/AN/AN/AN/AN/AOTLKOncobiologicsN/AN/AN/AN/AN/ATROVCardiff OncologyN/AN/AN/AN/AN/ATTNPTitan PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYTRLadRxN/AN/AN/ALIFEaTyr Pharma0.026.076.07OTLKOncobiologicsN/A0.670.54TROVCardiff Oncology0.122.372.37TTNPTitan PharmaceuticalsN/A11.6011.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYTRLadRxN/ALIFEaTyr Pharma61.72%OTLKOncobiologics11.20%TROVCardiff Oncology9.99%TTNPTitan Pharmaceuticals31.49%Insider OwnershipCompanyInsider OwnershipCYTRLadRxN/ALIFEaTyr Pharma3.70%OTLKOncobiologics4.80%TROVCardiff Oncology0.60%TTNPTitan Pharmaceuticals0.72%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYTRLadRxN/A45.04 millionN/ANot OptionableLIFEaTyr Pharma5669.01 million66.46 millionOptionableOTLKOncobiologics2044.42 million42.29 millionOptionableTROVCardiff OncologyN/A11.01 millionN/ANot OptionableTTNPTitan Pharmaceuticals101.33 million1.32 millionOptionableTTNP, OTLK, CYTR, LIFE, and TROV HeadlinesRecent News About These CompaniesTitan Pharmaceuticals, Inc. (NASDAQ:TTNP) Short Interest Down 22.1% in AugustSeptember 9, 2025 | americanbankingnews.comTitan Pharmaceuticals Approves Merger with Black TitanAugust 26, 2025 | msn.comTITAN PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Titan Pharmaceuticals, Inc. - TTNPAugust 5, 2025 | businesswire.comURGENT: The M&A Class Action Firm Encourages $hareholders to Act Before Vote – Titan Pharmaceuticals, Inc. (Nasdaq: TTNP)July 29, 2025 | globenewswire.comTitan Pharmaceuticals Inc (TTNP) - Investing.comJuly 4, 2025 | investing.comTitan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock - MorningstarJune 29, 2025 | morningstar.comMTitan Pharmaceuticals Completes Private Placement of Series C Convertible Preferred Stock with Blue Harbour Asset Management - NasdaqJune 29, 2025 | nasdaq.comTitan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred StockJune 27, 2025 | finance.yahoo.comTitan Pharmaceuticals Completes Private Placement of Series C Convertible Preferred Stock with Blue Harbour Asset ManagementJune 27, 2025 | quiverquant.comQTitan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred StockJune 27, 2025 | globenewswire.comtitan pharmaceuticals issues common stock following preferred stock conversionsJune 4, 2025 | investing.comTitan announces filing of registration statement for proposed combinationJune 4, 2025 | finance.yahoo.comTitan Pharmaceuticals, Inc. Files Registration Statement for Proposed Merger with TalenTec Sdn. Bhd.June 3, 2025 | quiverquant.comQTitan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd.June 3, 2025 | globenewswire.comTitan Pharmaceuticals Announces $1 Million Private Placement of Convertible Preferred StockApril 11, 2025 | globenewswire.comTitan Pharmaceuticals: Q4 Earnings SnapshotMarch 20, 2025 | sfgate.comTitan Pharmaceuticals receives Nasdaq notice of non-complianceNovember 27, 2024 | markets.businessinsider.comTitan Pharmaceuticals Faces Nasdaq Compliance Challenges with Reporting and Audit Committee RequirementsNovember 27, 2024 | quiverquant.comQTitan Pharmaceuticals, Inc. Announces Receipt of Notice from NasdaqNovember 27, 2024 | globenewswire.comSanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly BeatOctober 25, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMongoDB Roars Back to Life: It’s Not Too Late to Buy MoreBy Thomas Hughes | August 27, 20252 Reasons to Scoop Up Rubrik Stock and Hold on for LifeBy Thomas Hughes | September 11, 2025GameStop Returns to Growth, Don’t Expect Another Meme SpikeBy Thomas Hughes | September 11, 2025Biotech Sector May Flip to Market Leader by Year-EndBy Ryan Hasson | September 15, 20255 Clean Energy Stocks Poised for the Next Green RallyBy Ryan Hasson | September 8, 2025TTNP, OTLK, CYTR, LIFE, and TROV Company DescriptionsLadRx NASDAQ:CYTRLadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. The company was founded in 1985 and is headquartered in Los Angeles, CA.aTyr Pharma NASDAQ:LIFEaTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.Oncobiologics NASDAQ:OTLK$1.02 -0.06 (-5.09%) Closing price 04:00 PM EasternExtended Trading$1.03 +0.01 (+0.49%) As of 05:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.Cardiff Oncology NASDAQ:TROVCardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.Titan Pharmaceuticals NASDAQ:TTNP$4.30 -0.02 (-0.46%) Closing price 04:00 PM EasternExtended Trading$4.28 -0.02 (-0.58%) As of 05:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike’s Red-Hot Analyst Buzz: Is a Comeback Brewing? Broadcom Hits Record High After CEO Hock Tan AI Pay Package CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Why CoreWeave's NVIDIA Deal Creates a Deep Moat for AI Investors Resideo Technologies: Institutional Activity Signals 30% Upside This Stock Quietly Benefits From Oracle and NVIDIA’s AI Surge Rezolute Stock: FDA Fast Track Fuels 2025 Breakout Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
